though an effort to improve and document remedial procedures is required. However, failing the same analyte in two of three consecutive PT events can subject a laboratory to severe regulatory consequences, called an adverse action under CLIA-67. For CAP-90, adverse action was initiated with consecutive failures in three successive PT events for the same analyte. The CLIA-67 regimen also requires an overall pass rate of at least 80% of the samples across all the analytes in a particular subspecialty or specialty. Our analysis showed that, for all but the worst laboratories or for those doing only one or two tests, this is irrelevant, and we will not consider the across-analyte failure further.
used its 20 years of experience with PT to empirically set its pre-1991 evaluation criteria (4-7). We compare the old CAP-90 (i.e., in use in 1990) PT criteria with the new CUA-67 criteria for the subspecialty of routine chemistry listed in Table 1 . In 1991, all federally approved PT programs were required to use these new criteria as the minimum acceptable levels of performance.
Failure in one PT event in the CAP-90 program involving two samples per challenge was defined as one or two results per analyte falling outside the stated performance limit per shipment; for CLIA-67, it is two or more incorrect out of the five sample results. With either regimen, merely failing an analyte in one PT event does not subject a laboratory to any significant penalty, though an effort to improve and document remedial procedures is required. However, failing the same analyte in two of three consecutive PT events can subject a laboratory to severe regulatory consequences, called an adverse action under CLIA-67. For CAP-90, adverse action was initiated with consecutive failures in three successive PT events for the same analyte. The CLIA-67 regimen also requires an overall pass rate of at least 80% of the samples across all the analytes in a particular subspecialty or specialty. Our analysis showed that, for all but the worst laboratories or for those doing only one or two tests, this is irrelevant, and we will not consider the across-analyte failure further.
Along with the specification of minimum uniform PT performance requirements, the CLIA-67 regulations are distinctly more aggressive. Under this 'perform or else" approach, a laboratory is subject to adverse action on the basis of just one analyte failure and faces potential revocation of certification for the entire specialty or subspecialty. This could result in an order to immediately cease testing, unless the laboratory is allowed to voluntarily withdraw from testing the failed analyte(s). In the April 2, 1991, proposed sanctions, the Health Care Finance Administration indicated it would retain the right to initiate such vigorous action but suggested it would opt for less draconian intermediate sanctions (8) .
At present, laboratories have many years of experience with the CAP-90 PT program's grading criteria and regimen (two samples quarterly) and essentially no regulatory experience with the new CLIA-67 performance limits and regimen
(five samples quarterly).
Analyzing the PT processes, we have compared the two programs by relating intralaboratory performance pa- 
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rameters, CV and bias, to the chance of failing an analyte, and to the chance that an analyte will subject the laboratory to adverse action. To emphasize the relationship to, and familiarity with, the pre-1991 or old CAP regimen, we relate performance to actual group SDs for the respective analytes in recent CAP PT survey challenges.
Originally, PT programs were designed to stress peer comparison, education, and "constructive self-criticism." These programs sought to identify substandard performance, initially to the director and later to the regulator, with the implicit understanding that self-initiated corrective action would be taken (9, 10) . This nonthreatening, self-improvement approach is credited for the 40-plus years of continuous, incremental improvement in the quality of laboratory testing in the U.S. and Canada. Later, to meet regulatory needs, CAP reluctantly adopted the "three consecutive event failure" rule as the criterion for notifying the regulatory agency of substandard performance. The new CLIA-67 punitive regulatory stance will have a significant impact on the manner in which participants view participation in PT.
Materlais and Methods
Many studies document the nearly gaussian distribution of interlaboratory variation, i.e., group SD, as measured by PT over large groups of laboratories (11) . We therefore characterize the PT performance of a group of laboratories for one sample in one event by using the group mean and SD. Similarly, intralaboratory variation is also nearly gaussian; in this case the preferred parameters are bias (the systematic difference between the laboratory's measured mean value and a theoretical true value) and imprecision (the laboratory's internal day-to-day SD or CV). We have demonstrated previously, by computer modeling and statistical analysis, that intralaboratory performance (CV, bias) can be related directly to the probability of passing PT evaluation criteria (12) (13) (14) (15) (16) .
Utilizing actual pre-1991 CAP PT survey group means and SDs as benchmarks, one can compute the probability of failure under the CAP-90 and CLIA-67 performance limits and formats. On the basis of a gaussian distribution, a bias of zero, and a variable intralaboratory SD, we generate curves describingthe two-tailed probability of a laboratory producing one result outside PT limits. This is illustrated for the analyte total cholesterol in Figure 1 , as the curve labeled CLIA-67 Out. Treating the multiple samples in a PT event as a Bernoulli trial, and neglecting possible differences in performance as concentrations change, we derive a curve representing the probability of failing one event of five samples for one analyte, labeled CLIA-67 Fail in Figure 1 . Treating eight PT events (two years' worth) as a second Bernoulli trial, we then derive the curve labeled CLJA -67Adverse [8] , which shows how the probability that a laboratory will be subject to adverse action at least once within two years varies as a function of its possible intralaboratory SD values. This last step is more complex, because the adverse action rules depend on the pattern of event failures, and not just on their total number. In the CAP-90 format it is three consecutive failures; in CLIA-67 it is two of three consecutive event failures: The asterisks overlying the curves in Figure 1 highlight the points corresponding to an intralaboratory SD that is 131% of the pre-1991 CAP interlaboratory group SD, as detailed in the discussion of Table 3 . SDs of this magnitude will result in a nearly 100% probability of adverse action during a two-year period.
A further step can treat all 27 routine chemistry analytes as a third Bernoulli trial over the chance of adverse action, under the assumption of identical adverse action rates for each analyte. This produces an estimate of the overall chance that a laboratory will be subject to any adverse action, based on all of its analytes being tested simultaneously (which is the usual situation) in a single PT event. The basis for this three-stage binomial cascade is the gaussian distribution posited for the hypothetical laboratory. For a fixed small bias, the two-tailed chance of producing a result outside the PT limits increases monotonically with increasing SD; similarly, each binomial stage (i.e., progressing from a single error to event failure to adverse action) is a monotonically increasing function of the previous one (i.e., the curves get steeper). Therefore, one can pick a goal probability for the overall chance of ending with an adverse action and conduct a binary numeric search for the SD value that gives rise to this goal. Subsequently, we show analyses based on seeking an SD value that makes the CLIA-67 chance of overall adverse action approach 100%, and on limiting this chance to 1%. Similar analyses are done for the CAP-90 rules.
Results CLIA-67 defines minimum performance standards (target value ± a specified tolerance) for 27 routine chemistry analytes. In Table 1 , the CAP-90 (old) and CLIA-67 (new) performance standards are compared. Many of these cannot be compared a priori, because of changes between the approach used to specify limits. Some are based on absolute values, someon percentages of the target value, and others on multiples of the group SD. Table 2 shows CAP and CLIA-67 performance standards based on actual 1990 CAP survey data. We used these data for the analyses reported here. The representative group or interlaboratory means and SDs, selected from 1990 CAP surveys for each analyte, are methodspecific values, generally selected from high-quality systems in widespread use. Such actual CAP PT surveydetermined values are often deemed state-of-the-art performance. They contain elements of error attributable to local calibration, individual instrument imprecision, lotto-lot variation in reagents, and any additional variance from the PT samples (vial-to-vial differences), the handling and reconstitution processes,etc. Therefore, one can logically assume that, on a day-to-day basis within one laboratory, the observed intralaboratory SD should be smaller than an interlaboratory group SD. We use these empirically determined group SD values as benchmark points when analyzing the intralaboratory CVs needed to successfully pass PT. With these values in hand, CAP-90 and CLIA-67 performance limits can be computed a posteriori for all analytes. Restating the group SD as a percentage of the CLIA-67 performance limit (Table 2) is useful later when discussing the relative danger represented by the various internal CVs for specific analytes under the new rules.
Comparing minimum CAP-90 vs CLIA-67 PT performance criteria in Tables 1 and 2 indicates that 8 of the 27 CLIA-67 criteria for routine chemistry are quantitatively more stringent, i.e., have a smaller error tolerance with respect to the target value. Six CLIA-67 criteria are essentially the same as CAP-90. For some of the analytes the CAP-90 criteria were expressed as "± (n) SD" (i.e., based on some number, usually 2.0, times the group SD), whereas in the CLIA-67 scheme, the criteria are now absolute (i.e., alanine and aspartate aminotransferase require a result to be within ±25% of the target value). In general, for most of the tests with newly assigned absolute limits, the tolerances are less stringent.
Use of ±2 SD (group) performance limits (which theoretically about 1 in 20 participants fail) is proper in PT programs designed to alert the director to a possible intralaboratory problem but not when used to initiate regulatory sanctions. CAP-90, with its requirement of three consecutive failures before initiating sanctions, converted a PT-quality assurance program expecting to "fail" 5% of laboratories on a single PT event into a regulatory program in which a state-of-the-art laboratory had a 1:8000 chance of adverse action. In essence, CAP-90 tolerated a high rate of false-positive results for single events, but reported very few failures over multiple events. This approach was apparently unacceptable in a regulatory framework, because the CLIA-67 regulations seemingly increased the sample size to five in an effort to prevent failing an event because of random mischance. Conversely, CLIA-67 changed the criteria for adverse action from three consecutive failed events to two failed events (out of three), making the overall effect more complex.
While comparing CAP-90 and CLIA-67 PT perfor- 
Abbreviations as in Table 1. mance criteria, one may also consider the work of Cembrowski and Vanderlinde (17) , who demonstrated that most (-63%) laboratories routinely use the now The comparative data in Table 2 for analytes for which the CAP-90 tolerance is equal to or smaller than that of CLIA-67 are significant because of the a priori assumption that the CAP-90 PT criteria indeed are "reasonable"; that is, most laboratories in CAP-90 PT programs routinely passed and the data generally are accepted as reflecting the state of the art in laboratory performance. For the eight analytes for which CLIA-67 now requires a smaller internal imprecision for a passing performance, the laboratory that was previously performing acceptably under CAP-90 must now reevaluate its risk of PT failure. The implication is that significant numbers of marginal but acceptably performing CAP-90 laboratories may not be able to achieve the small CUA-67 imprecision mandated.
To meaningfully compare the two PT regimes, one cannot simply consider the changes in the performance limits; the changes in failure and adverse action rules must also be considered. Table 3 shows how the chance of producing a result outside the PT limits, the chance of failing a PT event, and the chance of incurring adverse action during a two-year period are affected under the two regimens for a laboratory whose performance is uniformly 131% of the CAP survey's group SD. This percentage was chosen as a valuable reference point because, under the new CLIA-67 regimen, it yields a near 100% probability of adverse action over 27 analytes within two years. We chose the two-year time frame to reflect the approximate sustained performance of the PT regime, while keeping the period short enough to be meaningful.
Considering total cholesterol in Table 3 , we see that, under CAP-90 limits, a laboratory with an SD at 131% of that of its peers has a 5.4% chance of producing one result outside the PT limit in a single event. The CLIA-67 limit is tighter, ±227.8 vs ±341.7 mg/L (Table  2) ; consequently, this same laboratory's chance of producing a single bad result under CLIA-67 rises to 19.9%. For CAP-90, one bad result out of two fails that analyte for that event, yielding a binomial probability slightly less than twice that of a single bad result. The CLIA-67 requirement of failing two or more results out of five is more complex; if the chance of a single result falling outside the PT limits is fairly small (e.g., <12%), the risk of a CLIA-67 PT event failure (at least two of five incorrect sample results) is less than for CAP. However, as in the case of total cholesterol, the two-of-five rule exaggerates larger values. Under CLIA-67, a laboratory with an internal CV equal to 131% of the group SD has a 26% chance of failing this analyte. An alternative way of conceptualizing this is as a plot of probability of failure (y) vs internal SD (x). The plot for the two-of-five rule (CLIA-67) has a steeper curve than the one-of-two rule (CAP-90). The two-of-five curve stays low longer, indicating fewer failures, and then rises faster. The analysis of the probability of adverse action is analogous to that of the single-event failure rule. CAP-90 requires failing three events in a row, which reduces a 10.5% chance of a single-event failure for cholesterol to a 0.6% chance of adverse action. At the same internal performance level, the CLIA-67 two-ofthree consecutive failures requirement increases a 26% chance of failing one event to a 47.5% chance of adverse action over the next eight events. Figure 2 shows four curves for total cholesterol analyses, two for CLIA-67 and two for CAP-90. Two of these are the CLIA-67 fail (one event) and CUA-67 adverse [8] curves from Figure 1 . Similarly, for the CAP-90 rules, one curve shows the chance of a single PT event failure (one of two or two of two PT values outside CAP-90 acceptable limits) and the other the chance of adverse action (failure in three consecutive PT events) during a two-year period. No curve is presented that corresponds to the chance of producing a single result outside of the PT limit. The maximum allowable internal SD consistent with avoiding an adverse action 99% of the time falls at 44% of the CLIA-67 performance limit (seeTable 4). As Figure 2 shows, a laboratory with performance equal to the group SD has a substantial chance of adverse action within eight PT events under the new CLIA-67 rules! Further, to the extent that the group SD is falsely small (because some laboratories presumably perform duplicate analyses), a laboratory should strive to reduce its imprecision, perhaps to a value 20% less than the group SD! The relative risk an analyte posesto the laboratory in a regulatory PT program can bejudged by the relationship of the 100% of group SD (Figure 2 , leftmost asterisks) to the 44% of the CLLA limit ( Figure  2, inward tick marks) . When the asterisks are near or to the right of the ticks, as in this case, actual laboratory imprecision borders on or exceeds safe values. In Table  2 , the last column showsthe ratio of the group SD to the CLIA-67 limit; ratios >33% are worrisome for a laboratory performing at the CAP-defined state of the art; Figure 3A shows curves analogous to those in Figure  2 , but for glucose. Because both cholesterol and glucose have performance limits of ± 10% (CLLA-67), the shapes are identical; however, the areas of critical interest are not. Again in this case, the CLIA-67 performance limit, whether judged on the basis of event failure or adverse action, is uniformly more stringent than CAP-90. Curve families for alanine aminotransferase, amylase, aspartate aminotransferase, creatine kinase, lactate dehydrogenase, biirubin, calcium, and high-density lipoprotein cholesterol are not shown, but are similar in shape and orientation to those for glucose, when actual survey data (Table 2 ) are used to specify the performance limits. The ratio of the group SD to CUA-67 limit (column 5 in Table 2 ) is less favorable (i.e., larger) for aspartate arninotransferase and bilirubin. Figure 3B shows similar curves for p02. Although the shapes of the curves in this and subsequent figures are the same as in the previous figures, the difference in PT limits leads to a difference in their location and crossing points. In this case,the chance of failing one event is less under CLIA-67 than under CAP-90. In fact, for small SD values, the risk of adverse action is substantially less under CLIA-67. Curve families for the analytes creatine kinase isoenzymes, lactate dehydrogenase isoenzymes, Pco2, albumin, total protein, triglycerides, and magnesium are similar in shape and orientation. However, for total protein, the group SD is typically much larger than the CLIA-67 performance limit; hence, average laboratories incur some risk of adverse action for this assay. Figure 3C showsthe failure and adverse action curves for blood pH. This is similar to Figure 3B , except the CLIA-67 limits are not dramatically larger than the CAP-90 ones, so the failure curves are closer, and the adverse action curves cross sooner. Curve families for alkaline phosphatase and creatinine are similar to those for pH. Figure 3D for chloride exhibits this CAP vs CLIA adverse action crossover even sooner. The CLIA-67 adverse action curve begins slightly lower than CAP-90, but its steeper nature is rapidly evident. Curves for total iron, blood urea nitrogen, uric acid, and potassium are similar to the curves for chloride. These analytes show substantially more risk under CLLA-67 than under CAP-90, although the exact level of peril varies, being low for potassium and high for blood urea nitrogen.
Obviously, a laboratory's internal imprecision as a percentage of the CLIA-67 limits will vary on an arialyte-by-analyte basis. However, one can generalize about the relationship between internal imprecision and PT performance criteria. Table 4 shows the practical limits a laboratory's internal CV must meet to ensure that the overall risk of an adverse action against at most 1 of the 27 analytes is <1% during a two-year period, assuming that each analyte exhibits equal risk. Table 4 must be interpreted with care because the adverse action curves shown in Figures 2 and 3 can be very steep near this point. A slight shift to the right for the internal performance of a single analyte (larger SD) may sharply increase the likelthood of PT failure for that analyte and an adverse action for the laboratory. A leftward shift (smaller SD) improves that analyte's chances of avoiding failure but does not help the laboratory that much in aggregate. The most dangerous analytes in this regard seem to be total cholesterol, bloodurea nitrogen, total protein, sodium, chloride, uric acid, and aspartate arninotransferase. Further, laboratories estimating their internal day-to-day imprecision typically have some inherent uncertainty associated with this measurement, including possible falsely low values due to discarding of "bad" internal qualitycontrol data. We feel that, on a practical basis, our original suggestion of one-third of the CLIA-67 value should be retained as a practical approach. Unfortunately, based on CAP-90 survey data, this appears to be feasible for only 15 of the 27 analytes for many laboratories.
It is important to understand that for a given laboratory analyzing PT specimens for all 27 analytes in the subspecialty of routine chemistry, if 26 are comfortably within the 33-44% of CLIA-67 tolerance zone, and the 27th analyte is at the 50th or 60th percentile, that last analyte will be the one determining the laboratory's senting the largest (>33%) percentages of the CLIA-67 tolerances and certainly any over 44%. In light of this, Table 4 represents a blueprint for survival.
Discussion
All of the above analyses are predicated on the assumption of zero bias. Previously we have shown that, for purposes of predicting PT performance, if the analytical bias is <20%, a laboratory's performance is dominated by its imprecision (SD) (12) . However, experience with PT programs shows that laboratories that fail due to analytical error typically do so because of large idiosyncratic bias (e.g., induced by the PT specimen matrix or errors in preparation), not large imprecision. A laboratory must make unrelenting efforts to keep its analytical bias small, so as to reap the benefits of its efforts to reduce imprecision. The obligation of PT programs is to remove the bias that originates with the specimens.
We have demonstrated that, in the absence of bias under the CAP-90 and CUA-67 PT formats, the intralaboratory CV, expressed as a function of the performance limit, can predict success. In the presenceof bias, the "allowable" CV decreases, which is consistent with the total allowable error approach.
The specifIc net effects of the changes in performance limits under CLIA-67 are difficult to characterize, be- Before laboratories that were successful under the CAP-90 system can conclude that CLIA-67 PT protocol will present few problems, they should consider which analytes place them at highest jeopardy. Although previous CAP surveys usually were not thought of in terms of problem analytes, actual 1990 CAP survey performance data and the new CLIA-67 rules suggest that assays of total cholesterol, total protein, and blood urea nitrogen may be the major source of PT problems. Of most concern is a potential CLIA-67 PT adverse action in one analyte, mandating suspension of testing in the entire subspecialty. For CAP-90, suspensions affected only the offending analyte(s); currently under CLIA-67, the entire subspecialty is at risk of suspension on the basis of any one of 27 analytes, unless a laboratory voluntarily stops testing the offending analyte. Such a selective withdrawal would conserve some hospital operations. However, this does not solve the so-called blood gas problem. if the offending analyte was Po2, suspension of this one critical analyte would seriously impair the ability of the hospital to provide most surgical procedures.
Our analysis clearly demonstrates that the likelihood of failing one PT event is generally slightly less under the CLIA-67 regimen. However, the chance of adverse action is occasionally greater, and of course, the potential penalties are much more severe. We suspect that the intent of the Health Care Financing Administration, which undoubtedly was based on an intuitive approach to setting performance limits, was to relax performance criteria enough to avoid excessive adverse action rates. There is some indication of this in their We have dealt only with the implications of the statistics, i.e., the relationship between internal imprecision and the likelihood of PT failure. With minimal bias, PT performance depends on the ratio of imprecision and the PT limits. In some cases, reducing intralaboratory imprecision to one-third of the CLIA-67 performance limits in Table 1 , the so-called "1/3" rule, is not technically feasible. We have discussed elsewhere (19) some strategies to legally enhance a laboratory's chances of passing PT. However, past experience has indicated that some laboratories will resort to "cheating" as defined by CLIA-67 (e.g., doing duplicate or triplicate tests) to ensure passing regulatory PT. Raising the stakes by using the "fail one; fail the subspecialty" rule will exacerbate, not relieve, this problem.
We do not think this is what Belk and Sunderman had in mind in 1947 (20).

